FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
The FDA has granted fast track designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue, clearing an expedited ...
The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.
In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with ...
Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
Oncology leaders weigh how to scale trustworthy AI platforms, align governance, and integrate care-research workflows for ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results